Patents by Inventor Kenneth J. Mandell

Kenneth J. Mandell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and use of varenicline for treating dry eye
    Patent number: 11911380
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 27, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903943
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903942
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903941
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Toxic aldehyde related diseases and treatment
    Patent number: 11771664
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: October 3, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • DRY EYE TREATMENTS
    Publication number: 20230226054
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • DRY EYE TREATMENTS
    Publication number: 20230226053
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • DRY EYE TREATMENTS
    Publication number: 20230226052
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • Toxic aldehyde related diseases and treatment
    Patent number: 11701331
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: July 18, 2023
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • DRY EYE TREATMENTS
    Publication number: 20220233528
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: December 6, 2021
    Publication date: July 28, 2022
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20220202745
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 30, 2022
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Methods of increasing lacrimal proteins
    Patent number: 11224598
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: January 18, 2022
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20210275469
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: April 12, 2021
    Publication date: September 9, 2021
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Toxic aldehyde related diseases and treatment
    Patent number: 11007157
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: May 18, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT
    Publication number: 20200368182
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Application
    Filed: January 27, 2020
    Publication date: November 26, 2020
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • METHODS OF TREATING OCULAR CONDITIONS
    Publication number: 20200345734
    Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.
    Type: Application
    Filed: April 17, 2020
    Publication date: November 5, 2020
    Inventors: Douglas Michael ACKERMANN, James LOUDIN, Kenneth J. MANDELL
  • DRY EYE TREATMENTS
    Publication number: 20200246336
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: September 10, 2019
    Publication date: August 6, 2020
    Inventors: Douglas Michael ACKERMANN, JR., James LOUDIN, Kenneth J. MANDELL
  • Methods of treating ocular conditions
    Patent number: 10709707
    Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: July 14, 2020
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, James Loudin, Kenneth J. Mandell
  • Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury
    Publication number: 20200147145
    Abstract: The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.
    Type: Application
    Filed: January 21, 2020
    Publication date: May 14, 2020
    Applicant: Noveome Biotherapeutics, Inc.
    Inventors: David L. Steed, Kenneth J. Mandell
  • Toxic aldehyde related diseases and treatment
    Patent number: 10588874
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 17, 2020
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell